Exploring a new epigenetic marker in Parkinson's Disease
Official title: Investigating Histone 3 Dopaminylation in Parkinson's Disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-10996999 · Data updated 2026-11-12
This study is looking at a new way that dopamine might affect brain proteins in people with Parkinson's Disease and dementia, hoping to find new treatments that could help slow down memory and movement problems.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 9, 2024 |
| Project end | September 8, 2028 |
| Funding year | 2024 |
| Award (this year) | $48,814 |
| NIH project number | 1F30AG090096-01 |
| Project ID | NIH-10996999 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Parkinson's Disease, particularly those who may be at risk of developing dementia.
✕Less likely to help
Patients with other forms of dementia unrelated to Parkinson's Disease may not benefit from this research.
What this research studies
This research investigates the role of a novel epigenetic marker, dopaminylation, in Parkinson's Disease (PD) and its associated dementia. The study focuses on how dopamine modifies histone proteins, which may influence the progression of neurodegeneration. By understanding these mechanisms, the research aims to identify potential therapeutic targets that could slow down or prevent the onset of dementia in PD patients. The approach involves examining the biochemical processes in the brain that contribute to both movement and cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of Parkinson's Disease and its related dementia.
How similar studies have gone: Previous research has shown promise in exploring epigenetic modifications in neurodegenerative diseases, indicating that this approach may yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Chen, Winnie — Icahn School of Medicine at Mount Sinai
- Study coordinator: Chen, Winnie
Related research
Other NIH-funded projects on the same topics.
-
Gut-brain clues in Parkinson’s disease: supplement to a large registry
A plant-wide supplement to an NIH program will enroll people with Parkinson’s, with and without GI symptoms, plus healthy controls, to study how gut function, brain signals, and sleep rhythms relate to Parkinson’s symptoms.
-
Gut-brain connections in Parkinson’s disease: how the gut and environment shape symptoms
A Mayo Clinic team is studying how gut problems, environmental factors, and genetics together influence Parkinson’s disease and its GI symptoms to find biomarkers and better understanding of the disease.
-
Gut-brain communication in Parkinson’s disease for better symptoms and daily life
This project enrolls people with Parkinson’s disease and healthy controls to build a big registry and study how gut function, brain signals, sleep, and circadian rhythms relate to PD symptoms.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
-
Understanding posture and movement in Parkinson’s patients to reduce falls
A study using wearable sensors to track real-world balance and movement in people with Parkinson’s disease to help prevent falls.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.